| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $110,109,160 ) (Continued on the next page) |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00HD108801 | Sex and physiological State dependent molecular characterization of circuits governing parental behavior | 001 | 4 | NIH | 8/14/2026 | $224,100 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA296401 | Rewired Lipid Metabolism Upon Spermine Synthase Inhibition In Colorectal Cancer Tumorigenesis | 000 | 1 | NIH | 8/20/2026 | $350,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R61DA064790 | Support Towards Addiction Recovery for Individuals with Criminal Legal System Involvement: The STAR Project | 000 | 1 | NIH | 2/24/2026 | $422,921 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | U2FFD008699 | University of Kentucky Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives | 002 | 2 | FDA | 7/27/2026 | $224,999 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL185125 | The role of Asprosin-Ptprd signaling in the neural control of blood pressure | 000 | 1 | NIH | 7/8/2026 | $724,259 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DE035485 | Baculovirus-Based Minimally Invasive Therapy for Head and Neck Squamous Cell Carcinoma | 000 | 1 | NIH | 8/10/2026 | $591,176 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA316685 | AI-Enhanced Methods for Cancer Surveillance: Improving Automated Information Extraction with DAC for Clinically Actionable Cancer Types | 000 | 1 | NIH | 8/11/2026 | $492,482 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL181997 | Developmental Programming of Cardiovascular Disease due to Prenatal Fentanyl Exposure | 000 | 1 | NIH | 8/10/2026 | $642,211 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | T32AI192234 | Transdisciplinary Training in Microbiology & Immunology | 000 | 1 | NIH | 8/10/2026 | $144,825 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AA032581 | Pituitary Adenylate Cyclase-Activating Peptide (PACAP) Action on Neurotransmission in the Extended Amygdala During Alcohol-Abstinence | 000 | 1 | NIH | 8/21/2026 | $536,524 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK148764 | Target PAQR4-Ceramide-GPNMB Pathway in MASH | 000 | 1 | NIH | 8/4/2026 | $736,529 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P20GM156679 | University of Kentucky Diabetes Prevention COBRE | 002 | 2 | NIH | 8/3/2026 | $2,264,219 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA066804 | Evaluating the Efficacy of Medial Prefrontal Cortex Accelerated Theta-Burst Stimulation for Cocaine Use Disorder: A Human Laboratory Inpatient Study | 001 | 1 | NIH | 8/11/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA066804 | Evaluating the Efficacy of Medial Prefrontal Cortex Accelerated Theta-Burst Stimulation for Cocaine Use Disorder: A Human Laboratory Inpatient Study | 000 | 1 | NIH | 8/7/2026 | $721,097 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS136272 | Harnessing engineered drug-free polymeric nanoformulations to reprogram innate immune cells for spinal trauma | 000 | 3 | NIH | 3/3/2026 | $326,594 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R35GM159612 | Targeting Membrane Environments: The Role of Oleate Hydratase (OhyA) in Lipid-Protein Interactions Across Microbial Communities | 000 | 2 | NIH | 7/16/2026 | $417,452 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P01AG078116 | Strategies for targeting astrocyte reactivity in Alzheimer's disease and related dementias | 000 | 5 | NIH | 7/3/2026 | $3,985,231 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R03DE035681 | Elucidating the etiology for Schneckenbecken dysplasia, a rare disease, using a vetrebrate model system | 000 | 1 | NIH | 2/17/2026 | $154,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG082339 | Genetic Architecture of Aging-Related TDP-43 and Mixed Pathology Dementia | 002 | 2 | NIH | 4/29/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG082339 | Genetic Architecture of Aging-Related TDP-43 and Mixed Pathology Dementia | 001 | 2 | NIH | 4/7/2026 | $84,564 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG082339 | Genetic Architecture of Aging-Related TDP-43 and Mixed Pathology Dementia | 000 | 2 | NIH | 3/26/2026 | $515,737 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R25AG092311 | Kentucky Postbaccalaureate Alzheimer’s Disease Research Education Program (KYPAD) | 000 | 2 | NIH | 6/18/2026 | $418,309 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AI197062 | Switches controlling bacteriophage lysis of the Lyme disease spirochete | 000 | 1 | NIH | 2/18/2026 | $420,063 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG097476 | RETURN: RECOVERY TO PHYSICALFUNCTION AFTER CRITICAL ILLNESS IN OLDER ADULTS | 001 | 1 | NIH | 8/14/2026 | $72,922 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG097476 | RETURN: RECOVERY TO PHYSICALFUNCTION AFTER CRITICAL ILLNESS IN OLDER ADULTS | 000 | 1 | NIH | 1/30/2026 | $382,830 |
| | 2026 | 2026 | University of Kentucky Research Foundation, The | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | 90DDUC0145 | University Centers for Excellence in Developmental Disabilities | 00 | 4 | ACL | 7/1/2026 | $629,042 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA064646 | Evaluation of the Combination Muscarinic Cholinergic Receptor Drug Product Cobenfy as a Medication for Cocaine Use Disorder Using Translational Human and Rat Cocaine Choice Procedures | 000 | 1 | NIH | 5/1/2026 | $663,978 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AG098189 | Decoding the Muscle Epitranscriptome: Deep Learning Detection of RNA Modifications in Aging Muscle | 000 | 1 | NIH | 1/21/2026 | $616,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AG098743 | Arginine Sensor (CASTOR1) Dysfunction Drives Tauopathy | 000 | 1 | NIH | 1/21/2026 | $423,500 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HD116429 | The role of glucocorticoid receptor in the ovary | 000 | 2 | NIH | 5/28/2026 | $643,408 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K01AG092253 | Feasibility, Acceptability, and Preliminary Efficacy of an HIV Prevention Intervention for Older Black Women | 000 | 2 | NIH | 8/18/2026 | $126,015 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK140148 | Role of Hypothalamic Adgrl1 in Counteracting Hypoglycemia | 000 | 2 | NIH | 4/13/2026 | $480,373 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R25CA302429 | Markey STRONG Scholars Program | 000 | 2 | NIH | 6/19/2026 | $223,823 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS138293 | Function of sphingoid bases in brain health and disease | 000 | 2 | NIH | 6/11/2026 | $377,030 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR084850 | Regulation of Myonuclear Turnover Dynamics in Multinucleated Muscle Cells | 000 | 2 | NIH | 6/12/2026 | $529,010 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F30AG099336 | Selective Targeting of Myeloid-derived APOE to improve safety and efficacy of anti-amyloid antibody therapy in Alzheimer’s Disease | 000 | 1 | NIH | 6/18/2026 | $38,914 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS142462 | Improving Disease-Modifying Therapy Uptake among Patients with Multiple Sclerosis | 000 | 1 | NIH | 6/19/2026 | $662,969 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R34CA313778 | Planning grant to support a future trial of an intervention to improve clinical trial education and enrollment | 000 | 1 | NIH | 6/19/2026 | $281,820 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR086163 | Slow and Fast Myosin Binding Protein-C in Human Skeletal Muscles | 000 | 1 | NIH | 7/29/2026 | $87,195 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR086163 | Slow and Fast Myosin Binding Protein-C in Human Skeletal Muscles | 000 | 1 | NIH | 7/29/2026 | $350,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA062746 | Impact of Cannabis on Opioid Self-Administration: Determining if Cannabis Alters the Drive to Take Opioids in Individuals with Opioid Use Disorder | 000 | 1 | NIH | 2/4/2026 | $647,142 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00DA056288 | Neurocognitive Impairments Resulting from Adolescent Prescription Opioid Use Disorder: Longitudinal Impact, Neural Mechanisms, and Comorbidities | 000 | 5 | NIH | 3/19/2026 | $249,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | T32DK138894 | Diabetes and ObesitY research training in kENtucky (DOYEN) | 000 | 2 | NIH | 7/28/2026 | $175,412 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS122028 | Reduced BBB Water Exchange as a Preclinical Biomarker of Small Vessel Disease | 001 | 3 | NIH | 3/5/2026 | $58,999 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS122028 | Reduced BBB Water Exchange as a Preclinical Biomarker of Small Vessel Disease | 000 | 3 | NIH | 1/30/2026 | $530,998 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HD116735 | Harnessing the inflammatory response to promote regeneration in mammals | 000 | 2 | NIH | 4/27/2026 | $657,560 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01ES030380 | Radon on the RADAR | 001 | 8 | NIH | 5/26/2026 | $514,461 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K08AI199235 | Mechanistic and Transcriptomic Modeling of Aztreonam/Avibactam vs. Aztreonam Plus Ceftazidime/Avibactam in Stenotrophomonas maltophilia | 000 | 1 | NIH | 5/28/2026 | $181,103 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21DE036083 | Juberg-Marsidi Syndrome: Exploring Its Causes. | 000 | 1 | NIH | 5/20/2026 | $444,438 |
|
